Apfelbeck Maria, Clevert Dirk-André, Stief Christian G, Chaloupka Michael
Urologische Klinik und Poliklinik des LMU Klinikums, Campus Großhadern, Ludwig-Maximilians-Universität München, Marchioninistr. 15, 81377, München, Deutschland.
Klinik und Poliklinik für Radiologie des LMU Klinikums, Campus Großhadern, Ludwig-Maximilians-Universität München, Marchioninistr. 15, 81377, München, Deutschland.
Urologe A. 2022 Apr;61(4):365-373. doi: 10.1007/s00120-022-01767-x. Epub 2022 Mar 4.
Despite the continuous technical progress regarding the transrectal ultrasonography of the prostate (TRUS) and its successful use in combination with magnetic resonance imaging (MRI) in MRI-targeted biopsy, there is no radiologic modality being able to rule out clinically significant prostate cancer without the need of systematic biopsy. In the past few years, TRUS regained more attention due to the development of high frequency ultrasound as well as the combination of different ultrasonic modalities like shear wave elastography and contrast-enhanced sonography (CEUS). Currently, multiparametric MRI (mpMRI)-targeted biopsy shows the best results concerning detection rates, sensitivity and specificity of clinically significant prostate cancer compared to systematic biopsy. In the future, transperineal biopsy is probably going to increasingly replace the transrectal biopsy approach. For both approaches, transrectal ultrasonography is necessary to display the prostate and to detect suspicious lesions. Therefore future improvements in transrectal ultrasonography can be expected.
尽管前列腺经直肠超声检查（TRUS）在技术上不断进步，且其与磁共振成像（MRI）联合用于MRI靶向活检取得了成功，但目前尚无一种影像学检查方法能够在无需系统活检的情况下排除临床显著性前列腺癌。在过去几年中，由于高频超声的发展以及剪切波弹性成像和对比增强超声（CEUS）等不同超声模式的联合应用，TRUS重新受到更多关注。目前，与系统活检相比，多参数MRI（mpMRI）靶向活检在临床显著性前列腺癌的检出率、敏感性和特异性方面显示出最佳结果。未来，经会阴活检可能会越来越多地取代经直肠活检方法。对于这两种方法，都需要经直肠超声检查来显示前列腺并检测可疑病变。因此，可以预期未来经直肠超声检查会有所改进。
